Brief: Alzamend Neuro Regains Compliance With Nasdaq Listing Standards
Brief: Alzamend Neuro Inc Entered Into An At--Market Issuance Sales Agreement
Brief: Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001
Alzamend Neuro Inc expected to post a loss of $5.50 a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended in April - Earnings Summary
Alzamend Neuro Inc expected to post a loss of $2.75 a share - Earnings Preview
Brief: Alzamend Neuro Files Prospectus Related To Resale Of Up To 125 Million Shares Of Common Stock, Of Co By Orchid Finance LLC - SEC Filing
Brief: Alzamend Neuro Announces Favorable Decision From Nasdaq Hearings Panel
Brief: Alzamend Neuro Announces Initial Closing Of Private Placement
Brief: Alzamend Neuro Announces Termination Of At-The-Market Equity Offering Program
Alzamend Neuro Inc reports results for the quarter ended in January - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Alzamend Neuro Files Non-Timely 10-Q With U.S. SEC-SEC Filng
Alzamend Neuro Inc expected to post a loss of 32 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 32 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Ameren Corp, Bread Financial Holdings, Exelon Corp
Alzamend Neuro Inc reports results for the quarter ended in October - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview